Endo International PLC (NASDAQ:ENDP) updated its FY17 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $3.35-3.65 for the period, compared to the Thomson Reuters consensus estimate of $3.53. The company issued revenue guidance of $3.38-3.53 billion, compared to the consensus revenue estimate of $3.49 billion.

Several research firms have recently weighed in on ENDP. Oppenheimer Holdings, Inc. reaffirmed a hold rating on shares of Endo International PLC in a research note on Tuesday. Royal Bank Of Canada lifted their price objective on Endo International PLC from $9.00 to $15.00 and gave the company a sector perform rating in a research note on Wednesday. Guggenheim began coverage on Endo International PLC in a research note on Saturday, June 17th. They issued a hold rating and a $12.00 price objective on the stock. BidaskClub lowered Endo International PLC from a hold rating to a sell rating in a research note on Monday, July 31st. Finally, Canaccord Genuity set a $12.00 price target on Endo International PLC and gave the stock a hold rating in a research report on Thursday, June 8th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have given a buy rating to the stock. The stock has an average rating of Hold and an average price target of $17.18.

Shares of Endo International PLC (NASDAQ:ENDP) traded up 2.93% during midday trading on Wednesday, hitting $8.42. The stock had a trading volume of 4,454,170 shares. The firm has a 50-day moving average of $11.36 and a 200 day moving average of $11.72. Endo International PLC has a 12-month low of $7.90 and a 12-month high of $24.93. The firm’s market cap is $1.88 billion.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The company had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. During the same quarter last year, the company earned $0.86 EPS. The company’s quarterly revenue was down 4.9% on a year-over-year basis. On average, analysts expect that Endo International PLC will post $3.53 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Endo International PLC (ENDP) Releases FY17 Earnings Guidance” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/09/endo-international-plc-endp-releases-fy17-earnings-guidance.html.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Earnings History and Estimates for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.